Haleon takes hit from ‘weak cold and flu season’ but Sensodyne shines April 29, 2026 After being spun out from GSK in the biggest London IPO in decades, City analyst are looking for more from the emblematic FTSE 100 consumer healthcare powerhouse with roots in a Lombard Street apothecary shop Fewer sniffles during the winter have sent a chill through sales volumes at Haleon, the FTSE 100 over-the-counter remedy maker. [...]
GSK to acquire US biotech group for $2.2bn January 20, 2026 FTSE 100 giant GSK has reached an agreement to acquire US based biotech group Rapt Therapeutics. The deal values the company, which develops therapies for treating people with inflammatory and immunologic diseases, at $2.2bn (£1.6bn), and marks the first major deal for new GSK chief executive Luke Miels, coming just weeks after he took charge [...]
Hikma: FTSE 100 giant’s boss replaced by former chief after share price woes December 15, 2025 The boss of FTSE 100 giant Hikma Pharmaceuticals will be replaced by the firm’s former top chief after the group’s share price dropped by nearly a quarter this year. Riad Mishlawi has exited his role as chief executive at Hikma, with executive chairman Said Darwazah to step into the post with “immediate effect”. It ends [...]
Vitabiotics: Profit cut ahead of of potential £1bn sale December 9, 2025 Profit at Vitabiotics, the pharmaceutical giant owned by former Dragons’ Den star Tej Lalvani, has been cut ahead of a potential £1bn sale. Reports emerged towards the start of 2025 that the London-headquartered business had revived plans to sell itself in a move which valued it at £1bn. At the start of December it was [...]
UK and US agree to zero tariff deal on pharmaceuticals December 1, 2025 The government has agreed to a major deal with Washington that will see the UK become the only country to secure zero import tariffs on pharmaceutical products into the US for at least three years. The deal follows months of negotiations between the government and the Trump administration, after the June trade deal left the [...]
Astrazeneca injects $2bn to boost US manufacturing capabilities November 24, 2025 FTSE 100 giant Astrazeneca plans to invest $2bn into growing its manufacturing footprint in Maryland, as part of its efforts to boost its US capabilities and presence. The investment will support the “significant expansion” of its biologics manufacturing facility in Frederick, doubling its capacity and increasing its medicine supply, as well as the construction of [...]
Astrazeneca vows to lower US medicine prices after pressure from Trump October 13, 2025 Astrazeneca has bowed to pressure from US president Donald Trump to lower the cost of its medicines for patients in America. The Cambridge-based pharma giant said it will provide direct-to-consumer sales to eligible patients with prescriptions for chronic diseases at a discount of up to 80 per cent off list prices, alongside participating in the [...]
Ministers planning drug pricing shake-up to stem pharma exodus October 8, 2025 Ministers are drawing up a radical overhaul of NHS spending rules in a bid to shore up the UK’s world-leading life sciences industry after a string of pharma giants cancelled major UK investment projects. In what would amount to one of the largest shake-ups of NHS drug purchasing rules in recent history, the Prime Minister [...]
Astrazeneca to ‘upgrade’ US listing in latest blow to London Stock Exchange September 29, 2025 Astrazeneca has laid out plans aimed at “upgrading” its US listing in the latest blow to the London Stock Exchange. The Cambridge-based pharma giant said it would replace its existing Nasdaq listing of American Depositary Receipts (ADRs), a type of listing for trading overseas shares, with a direct listing of ordinary shares on the New [...]
GSK shares rally as chief Emma Walmsley to exit after eight years September 29, 2025 The chief executive of pharmaceutical giant GSK has announced plans to step down from the company at the end of the year. Emma Walmsley, who took the helm of the drugmaker in 2017, will be replaced by chief commercial officer Luke Miels. Miels – the former Executive Vice President of Astrazeneca – also joined the [...]